2017 American Transplant Congress
Rejection of Human Kidney Allografts According to BANFF Classification Is Associated with a Chemokine-Enriched Protein Microenvironment in Biopsy Tssue.
Background: Expression profiling efforts of biopsy tissue after kidney transplantation indicate that rejection can be defined by distinct signatures. Based on pathological evaluation (BANFF) as…2017 American Transplant Congress
PPAR-γ Agonist Attenuates Hepatic Ischemia-Reperfusion Injury in a Mouse Model by Regulating Kupffer Cell Polarization.
PPAR-γ agonists have shown protective effect on ischemia-reperfusion injury (IRI) in cerebral and renal tissue. The effects of PPAR-γ on hepatic IRI is unclear. We…2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.
Background: Tacrolimus, which plays a backbone in immunosuppressive therapy, has a different effect in absorption according to intraindividual and interindividual variability, and it is a…2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…2017 American Transplant Congress
The Impact of Early Clinical and Subclinical T Cell Rejection After Kidney Transplantation.
Medicine and Surgery, University of Pittsburgh, Pittsburgh, PA
Purpose: To evaluate the impact of early Clinical(C-TCMR) and Sub-Clinical(SC-TCMR) T Cell Mediated Rejection on short-term allograft histology and function.Methods: We examined adult kidney alone…2017 American Transplant Congress
Obesity Is an Important Factor in Deceased but Not Living Donor Kidney Transplants.
Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom
Introduction There is an increasing obesity among potential kidney transplant recipients. We had in the past shown that obesity did increase the wound infection rate,…2017 American Transplant Congress
Strategies to Promote Pediatric Kidney Transplant Program in China – A Coming Opportunity with Development of Pediatric Deceased Donation.
Introduction This article demonstrates the opportunity and challenges of current pediatric kidney transplant program in China, based on the analysis study of the national registry…2017 American Transplant Congress
Impairment of Glucose Tolerance After Pediatric Kidney Transplant Is Associated with Worse Systemic Insulin Sensitivity Rather Than Fall in Insulin Secretion.
Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Hokkaido, Japan
Introduction and Objective: Tacrolimus and steroid are considered to affect insulin secretion and insulin sensitivity, respectively, resulting in worse glucose tolerance after pediatric kidney transplant…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 181
- Next Page »